FindTrial
Sign In

Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer

Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer

Status
Unknown
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080220199
Enrollment
Unknown
Registered
2006-01-25
Start date
2006-01-25
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unresectable Colorectal Cancer

Interventions

investigational material(s) Generic name etc : Irinotecan hydrochloride | Tegafur/Gimeracil/ Oteracil Potassium | Fluorouracil | Levofolinate Calcium INN of investigational material : Therapeutic cat

Sponsors

Taiho Pharmaceutical Co., Ltd. DAIICHI SANKYO Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Histologically confirmed colorectal cancer Locally advanced and/or metastatic colorectal cancer Have prior chemotherapy as first line treatment Age 20 to 75 Performance status 0 or 1 (ECOG)

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Progression free survival—

Contacts

Public Contact; ;

Taiho Pharmaceutical Co., Ltd.;DAIICHI SANKYO Co., Ltd.

;;

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026